Literature DB >> 28003728

Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma.

Swastik Agrawal1.   

Abstract

Entities:  

Year:  2016        PMID： 28003728      PMCID： PMC5157915          DOI： 10.1016/j.jceh.2016.11.001

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  13 in total

1.  A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  Lorenza Rimassa; Tiziana Pressiani; Corrado Boni; Carlo Carnaghi; Elena Rota Caremoli; Stefano Fagiuoli; Paolo Foa; Stefania Salvagni; Enrico Cortesi; Maria Chiara Tronconi; Nicola Personeni; Silvia Bozzarelli; Maria Chiara Banzi; Silvia Fanello; Fabio Romano Lutman; Laura Giordano; Armando Santoro
Journal:  Oncologist       Date:  2013-04-11

2.  Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Authors:  Michael Bitzer; Marius Horger; Edoardo G Giannini; Tom M Ganten; Marcus A Wörns; Jens T Siveke; Matthias M Dollinger; Guido Gerken; Max E Scheulen; Henning Wege; Vittorina Zagonel; Umberto Cillo; Franco Trevisani; Armando Santoro; Vincenzo Montesarchio; Nisar P Malek; Julia Holzapfel; Thomas Herz; Astrid S Ammendola; Stefano Pegoraro; Bernhard Hauns; Anna Mais; Ulrich M Lauer; Stefan W Henning; Bernd Hentsch
Journal:  J Hepatol       Date:  2016-03-04       Impact factor: 25.083

3.  The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients.

Authors:  Jing-Houng Wang; Chi-Sin Changchien; Tsung-Hui Hu; Chuan-Mo Lee; Kwong-Ming Kee; Chih-Yun Lin; Chao-Long Chen; Tai-Yi Chen; Yu-Jie Huang; Sheng-Nan Lu
Journal:  Eur J Cancer       Date:  2008-03-11       Impact factor: 9.162

4.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Authors:  Philip J Johnson; Shukui Qin; Joong-Won Park; Ronnie T P Poon; Jean-Luc Raoul; Philip A Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Aviña; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

5.  Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.

Authors:  Takashi Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Tadatoshi Takayama; Namiki Izumi; Masumi Kadoya; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Shuichi Kaneko; Norihiro Kokudo
Journal:  J Hepatol       Date:  2016-06-04       Impact factor: 25.083

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 9.  Epigenetics in liver disease.

Authors:  Derek A Mann
Journal:  Hepatology       Date:  2014-05-07       Impact factor: 17.425

10.  Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Authors:  Calin Cainap; Shukui Qin; Wen-Tsung Huang; Ik Joo Chung; Hongming Pan; Ying Cheng; Masatoshi Kudo; Yoon-Koo Kang; Pei-Jer Chen; Han-Chong Toh; Vera Gorbunova; Ferry A L M Eskens; Jiang Qian; Mark D McKee; Justin L Ricker; Dawn M Carlson; Saied El-Nowiem
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544
View more
  1 in total

1.  Evolvulus alsinoides methanolic extract triggers apoptosis in HepG2 cells.

Authors:  Murugan Ponselvi Induja; Devaraj Ezhilarasan; Nandigam Ashok Vardhan
Journal:  Avicenna J Phytomed       Date:  2018 Nov-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.